Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: ISB 1302 250 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|BIOLOGICAL: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|BIOLOGICAL: ISB 1302 escalating doses,1200 ng/kg D15,22|BIOLOGICAL: ISB 1302 at the MTD and/or RP2D dose
Sponsor: Ichnos Sciences SA
Collaborators: Glenmark Pharmaceuticals S.A.